Inventor
BURKE ROB
US43 patents
⚠️ This page may combine multiple inventors who share the name “BURKE ROB”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AVIDITY BIOSCIENCES INC
40 patentsUS10550188B2Feb 4, 2020
Nucleic acid-polypeptide compositions and uses thereof
AVIDITY BIOSCIENCES INC80 citations98
US11179472B2Nov 23, 2021
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
AVIDITY BIOSCIENCES INC35 citations97
US10994020B2May 4, 2021
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
AVIDITY BIOSCIENCES INC32 citations97
US10881743B2Jan 5, 2021
Compositions and methods of treating muscle atrophy and myotonic dystrophy
AVIDITY BIOSCIENCES INC55 citations97
US12064483B2Aug 20, 2024
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
AVIDITY BIOSCIENCES INC19 citations94
US11400163B2Aug 2, 2022
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
AVIDITY BIOSCIENCES INC26 citations94
US11311627B1Apr 26, 2022
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
AVIDITY BIOSCIENCES INC28 citations94
US11555190B2Jan 17, 2023
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
AVIDITY BIOSCIENCES INC15 citations93
US11525137B2Dec 13, 2022
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
AVIDITY BIOSCIENCES INC13 citations93
US11110180B2Sep 7, 2021
Nucleic acid-polypeptide compositions and uses thereof
AVIDITY BIOSCIENCES INC19 citations93
US10787519B2Sep 29, 2020
Nucleic acid-polypeptide compositions and uses thereof
AVIDITY BIOSCIENCES INC19 citations93
US10487149B2Nov 26, 2019
Nucleic acid-polypeptide compositions and uses thereof
AVIDITY BIOSCIENCES INC21 citations93
US11912779B2Feb 27, 2024
Compositions and methods of treating facioscapulohumeral muscular dystrophy
AVIDITY BIOSCIENCES INC6 citations85
US11576980B2Feb 14, 2023
Compositions and methods of treating muscle atrophy and myotonic dystrophy
AVIDITY BIOSCIENCES INC6 citations85
US11446387B2Sep 20, 2022
Compositions and methods of treating muscle dystrophy
AVIDITY BIOSCIENCES INC8 citations85
US11253607B2Feb 22, 2022
Compositions and methods of treating muscle atrophy and myotonic dystrophy
AVIDITY BIOSCIENCES INC7 citations85
US11246941B2Feb 15, 2022
Compositions and methods of treating muscle atrophy and myotonic dystrophy
AVIDITY BIOSCIENCES INC7 citations85
US11554176B2Jan 17, 2023
Compositions and methods of treating muscle atrophy and myotonic dystrophy
AVIDITY BIOSCIENCES INC2 citations84
US11497814B2Nov 15, 2022
Compositions and methods of treating muscle atrophy and myotonic dystrophy
AVIDITY BIOSCIENCES INC3 citations84
US10800848B2Oct 13, 2020
Nucleic acid-polypeptide compositions and uses thereof
AVIDITY BIOSCIENCES INC7 citations83
US12427202B2Sep 30, 2025
Compositions and methods of treating muscle dystrophy
AVIDITY BIOSCIENCES INC1 citations74
US11583591B2Feb 21, 2023
Compositions and methods of treating muscle atrophy and myotonic dystrophy
AVIDITY BIOSCIENCES INC2 citations73
US12157774B2Dec 3, 2024
Compositions and methods of treating facioscapulohumeral muscular dystrophy
AVIDITY BIOSCIENCES INC1 citations72
US12104156B2Oct 1, 2024
Compositions and methods of treating facioscapulohumeral muscular dystrophy
AVIDITY BIOSCIENCES INC1 citations72
US12071485B2Aug 27, 2024
Compositions and methods of treating facioscapulohumeral muscular dystrophy
AVIDITY BIOSCIENCES INC2 citations72
US12049629B2Jul 30, 2024
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
AVIDITY BIOSCIENCES INC2 citations72
US11999955B2Jun 4, 2024
Compositions and methods of treating facioscapulohumeral muscular dystrophy
AVIDITY BIOSCIENCES INC2 citations72
US11872287B2Jan 16, 2024
Compositions and methods of treating muscle atrophy and myotonic dystrophy
AVIDITY BIOSCIENCES INC1 citations72
US11707532B2Jul 25, 2023
Compositions and methods of treating muscle dystrophy
AVIDITY BIOSCIENCES INC3 citations72
US11364302B1Jun 21, 2022
Nucleic acid-polypeptide compositions and uses thereof
AVIDITY BIOSCIENCES INC2 citations71
US12529056B2Jan 20, 2026
Compositions and methods of treating facioscapulohumeral muscular dystrophy
AVIDITY BIOSCIENCES INC0 citations62
US12486328B2Dec 2, 2025
Compositions and methods of treating facioscapulohumeral muscular dystrophy
AVIDITY BIOSCIENCES INC0 citations62
US12365704B2Jul 22, 2025
Nucleic acid-polypeptide compositions and uses thereof
AVIDITY BIOSCIENCES INC0 citations62
US12351637B2Jul 8, 2025
Nucleic acid-polypeptide compositions and uses thereof
AVIDITY BIOSCIENCES INC0 citations62
US12234290B2Feb 25, 2025
Nucleic acid-polypeptide compositions and uses thereof
AVIDITY BIOSCIENCES INC0 citations62
US11712478B2Aug 1, 2023
Compositions and methods of treating muscle atrophy and myotonic dystrophy
AVIDITY BIOSCIENCES INC0 citations62
US11578090B2Feb 14, 2023
Nucleic acid-polypeptide compositions and uses thereof
AVIDITY BIOSCIENCES INC1 citations62
US12364769B2Jul 22, 2025
Nucleic acid-polypeptide compositions and uses thereof
AVIDITY BIOSCIENCES INC0 citations61
US12263224B2Apr 1, 2025
Compositions and methods of treating muscle atrophy and myotonic dystrophy
AVIDITY BIOSCIENCES INC0 citations61
US10844385B2Nov 24, 2020
Beta-catenin nucleic acids and uses thereof
AVIDITY BIOSCIENCES INC0 citations51
MERCK SHARP & DOHME
3 patentsUS10532068B2Jan 14, 2020
Dual molecular delivery of oligonucleotides and peptide containing conjugates
MERCK SHARP & DOHME3 citations71
US10010562B2Jul 3, 2018
Dual molecular delivery of oligonucleotides and peptide containing conjugates
MERCK SHARP & DOHME3 citations71
US10239957B2Mar 26, 2019
Peptide containing conjugates for dual molecular delivery of oligonucleotides
MERCK SHARP & DOHME0 citations39